Innovent Biologics

Overview
Activities
News
Biosimilars?
Large-molecule Therapeutics?
Product stageSegments
Early
?
Diversified Drug Developers
?

Innovent Biologics, Inc. is a world-class biopharmaceutical company founded in 2011 that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases. The company has built a robust pipeline of 36 valuable assets, including 22 in oncology. As of 2024, Innovent has launched 10 products in the market, including TYVYT (sintilimab injection), BYVASDA (bevacizumab biosimilar injection), SULINNO (adalimumab biosimilar injection), HALPRYZA (rituximab biosimilar injection), PEMAZYRE (pemigatinib oral inhibitor), olverembatinib, CYRAMZA (ramucirumab injection), Retsevmo (selpercatinib capsules), FUCASO (equecabtagene autoleucel injection) and SINTBILO (tafolecimab injection). The company has four new drug applications under regulatory review, five assets in Phase III or pivotal clinical trials, and 18 more molecules in early clinical stage. Innovent's research and development strategy is centered on global innovation, with a focus on the "IO + ADC" approach in oncology. The company has established manufacturing facilities in Suzhou and Hangzhou, with a total antibody production capacity of 230,000L. In 2023, Innovent reported total revenue of RMB6,206.1 million, an increase of 36.2% compared to 2022.


Sources

Disclaimer: This company profile has been generated using data obtained through automated web searches and advanced generative AI technology. While we strive to ensure the accuracy and reliability of our sources, auto-generated information could be outdated or inaccurate and should be verified independently.
HQ location:
168 Dongping Street Suzhou Industrial Park Suzhou CHN
Founded year:
2011
Employees:
5,001-10,000
IPO status:
Public
Total funding:
USD 868.3 mn
Last Funding:
USD 308.3 mn (Post IPO Equity; Aug 2022)
Last valuation:
USD 1.0 bn (Apr 2018)
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.